An unusual placebo effect in Aligos Therapeutics’ Phase IIa trial is driving shareholder skepticism for its metabolic ...

Novo Nodrisk’s cannabinoid receptor–targeting obesity pill was picked up in the $1.1 billion acquisition of Inversago ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of ...